Snowden Capital Advisors’s Artelo Biosciences ARTL Stock Holding History

Snowden Capital Advisors’s Portfolio ARTL Stock Details ARTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-407	Closed	-$34K	–	1113
2022 Q2	$34K	Hold	407	–	–	﹤0.01%	1103
2022 Q1	$49K	Buy	+407	New	+$46.7K	﹤0.01%	1011

Other funds holding ARTL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Snowden Capital Advisors's ARTL Position: Q3 2022 in Review

Snowden Capital Advisors sold out of Artelo Biosciences (ARTL) in Q3 2022, closing a stake of 407 shares — an estimated $34K sold.

Snowden Capital Advisors first reported a position in ARTL in Q1 2022 and held it in 2 quarters. The position peaked at $49K in Q1 2022. 9 funds tracked by Wall St. Rank hold ARTL as of Q3 2022.

Snowden Capital Advisors reported no remaining Artelo Biosciences position as of Q3 2022 after selling out during the quarter.
Snowden Capital Advisors sold 407 Artelo Biosciences shares in Q3 2022, an estimated $34K.
Snowden Capital Advisors first reported a position in Artelo Biosciences in Q1 2022 and held it in 2 quarters.
Snowden Capital Advisors's Artelo Biosciences position peaked at $49K in Q1 2022.
9 funds tracked by Wall St. Rank held Artelo Biosciences as of Q3 2022.

Based on Snowden Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.